Pasar al contenido principal

Diana Fernandes de Rafael

I possess a Master in Pharmaceutical Sciences (2010) granted by the Faculty of Pharmacy from the Lisbon University, and a PhD degree in Pharmaceutical Technology (2017) from the same University. During my PhD I had the opportunity to do research stays at Ludwig Maximillian University (LMU), Munich, Bellvitge Biomedical Research Institute (IDIBELL) and Vall D'Hebron Research Institute (VHIR), Barcelona. Actually, I am a post-doctoral researcher at Drug Delivery and Targeting Group, VHIR working in the field of nanotechnology-based drug delivery systems applied to several diseases.

Instituciones de las que forman parte

Investigador/a principal
Bioquímica Clínica, Vehiculización de Fármacos y Terapia
Vall Hebron Institut de Recerca
Diana Fernandes de Rafael

Diana Fernandes de Rafael

Diana Fernandes de Rafael

Instituciones de las que forman parte

Investigador/a principal
Bioquímica Clínica, Vehiculización de Fármacos y Terapia
Vall Hebron Institut de Recerca

I possess a Master in Pharmaceutical Sciences (2010) granted by the Faculty of Pharmacy from the Lisbon University, and a PhD degree in Pharmaceutical Technology (2017) from the same University. During my PhD I had the opportunity to do research stays at Ludwig Maximillian University (LMU), Munich, Bellvitge Biomedical Research Institute (IDIBELL) and Vall D'Hebron Research Institute (VHIR), Barcelona. Actually, I am a post-doctoral researcher at Drug Delivery and Targeting Group, VHIR working in the field of nanotechnology-based drug delivery systems applied to several diseases.

Being a multidisciplinary scientist, during 10 years of research career I acquired expertise in different areas of knowledge such as Pharmaceutical Technology, Nanomedicine, Chemistry, Molecular Biology, Cancer Signalling Pathways, Preclinical Validation, etc. My board knowledge in the field of biomedical sciences granted by my training as pharmacist and my research experience, allowed me to have a comprehensive and integrative view of the different stages of drug development from the bench to the bedside. My career has been fully dedicated to the design, development, and preclinical validation of innovative delivery systems for a wide range of challenging diseases with a special attention to oncology.
My active participation at different international projects (12) and collaborations with a variety of research groups have resulted in the authorship of several publications in high impact peer-reviewed journals (35 publications, 15 as corresponding/first author, h-index 18). Also, she is co-inventor of two patents about delivery systems for gene delivery and the creation of cell penetrating peptides. Moreover, I am truly active in science dissemination both to share the knowhow with the pairs at international conferences, and also in citizenship dissemination actions. Additionally, due to her experience in the fields of Pharmaceutical Technology and Molecular Biology, I am giving classes at the Master of Molecular Biotechnology from the University of Barcelona. Most importantly, I was responsible for the supervision of the thesis of different pre-graduated, master and PhD students (14).

Proyectos

diVHulga. Programa anual de actividades UCC+I del Campus Vall d’Hebron (VH)

IP: Immaculada Hernández Rodríguez
Colaboradores: Josep Quer Sivila, Sara Ruiz Gallardo, Mayte Serrat Lopez, Julia Basallote Garciade Quiros, Beatriz Blasco Perez, Ariadna Laguna Tuset, Diana Fernandes de Rafael
Entidad financiadora: Fundación Española Ciencia y Tecnología (FECYT)
Financiación: 30000
Referencia: FCT-23-19812
Duración: 01/07/2024 - 30/06/2025

Evaluation of an innovative strategy based on nanoparticles-loaded hydrogels as a safe and sustained intraperitoneal chemotherapy in mucinous adenocarcinomas

IP: Fernanda Raquel Da Silva Andrade
Colaboradores: Roser Ferrer Costa, Julia German Cortes, Angels Alcina Mila, Diana Fernandes de Rafael
Entidad financiadora: Asociación Española Contra el Cáncer
Financiación: 10000
Referencia: SNRGS247164DASI
Duración: 01/06/2024 - 31/05/2026

Nanoclustered Affimers for Targeted KRAS Ablation in Pancreatic Ductal Adenocarcinoma

IP: Joaquin Seras Franzoso
Colaboradores: Diana Fernandes de Rafael
Entidad financiadora: Asociación Cáncer de Páncreas
Financiación: 50000
Referencia: ACANPAN/PROJECTES/2023/SERAS
Duración: 05/12/2023 - 04/12/2025

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Colaboradores: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Perez Dueñas, Belen, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Ariadna Boloix Amenós, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Cazurro Gutierrez, Ana Laura, Gómez Andrés, David, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 2494527.53
Referencia: FORT23/00034
Duración: 01/01/2024 - 31/12/2027

Noticias relacionadas

La Alianza Europea para la Investigación de Enfermedades Raras (ERDERA) se pusó en marcha en septiembre, con un presupuesto estimado de 380 millones de euros y el objetivo de mejorar la vida de pacientes con enfermedades minoritarias.

Mediante tomografía computerizada (TAC), con o sin contraste, es posible realizar una detección precisa y segura de la enfermedad sin necesidad de biopsias y evitando las limitaciones de otras herramientas diagnósticas no invasivas.

El proyecto europeo, en el que participa Vall d’Hebron, favorecerá el diagnóstico personalizado y estrategias terapéuticas innovadoras en pacientes con la enfermedad.

Profesionales relacionados

David Garcia Relancio

David Garcia Relancio

Técnico de investigación
Leer más
Ana Belén  Méndez Fernández

Ana Belén Méndez Fernández

Investigador postdoctoral
Enfermedades Cardiovasculares
Leer más
Miquel Roig Moline

Miquel Roig Moline

Personal de mantenimiento y servicios generales
Patologia Molecular Translacional
Leer más
Gemma Aran Canals

Gemma Aran Canals

Investigador postdoctoral
Medicina Transfusional
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.